MedPath

A study to verify the efficacy of the selective SGLT2 inhibitor tofogliflozin hydrate in reducing nocturia

Not Applicable
Recruiting
Conditions
octuria coexisting with diabetes
Registration Number
JPRN-UMIN000049753
Lead Sponsor
Department of Urology, Kouseikai Takai Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
50
Inclusion Criteria

Not provided

Exclusion Criteria

HbA1c >8.5% eGFR <45 mL/min/1.73m^2

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Change in nocturnal micturition frequency after 4 weeks
Secondary Outcome Measures
NameTimeMethod
(1) Changes after 4 weeks: 24-hour urine volume, nocturnal urine volume, nocturnal polyuria index, N-QOL, PSQI (2) Comparison at enrollment and 4 weeks later: HbA1c, serum Na
© Copyright 2025. All Rights Reserved by MedPath